HOME >> MEDICINE >> NEWS
Statin therapy cost-effective for a wider range of individuals

Statin therapy is cost-effective for a wider range of individuals with vascular disease or diabetes than previously recognised, concludes a study published online today (Thursday May 12, 2005) by THE LANCET.

Current guidelines generally recommend the initiation of statin therapy when the estimated 10-year risk of a non-fatal heart attack or coronary death is at least 15-20%.

The Heart Protection Study (HPS) has previously shown that lowering cholesterol concentrations with 40mg of simvastatin daily produces substantial reductions not just in the rates of such coronary events, but also in the rates of strokes and revascularisation procedures among a wide-range of high-risk individuals, irrespective of their pre-treatment blood cholesterol concentrations. In the HPS, over 20,500 adults aged 40-80 years with vascular disease or diabetes were randomly assigned to 40mg of simvastatin daily or a placebo. In the latest study the HPS researchers compared the costs of hospitalisations and statin therapy between the two groups, and estimated the cost-effectiveness for participants with varying levels of vascular disease risk.

They found a 22% relative reduction in the costs of hospitalisations for vascular events in the statin group, with similar proportional reductions in every sub-category of patients studied. Overall, the cost of avoiding a major vascular event was estimated to be 11,600, but there was substantial variation between the risk subgroups. For example, among individuals with a 42% 5-year risk of a major vascular event, the estimated cost-effectiveness was 4,500 per major vascular event avoided. By contrast, among those with a 12% 5-year risk, it was estimated to be 31,100. The authors believe that initiation of statin therapy should now be considered for people at lower risk for coronary or other major vascular events than is currently recommended.

Professor Rory Collins (Clinical Trial Service Unit, University of Oxford, UK), p
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
11-May-2005


Page: 1 2

Related medicine news :

1. Statin drugs may delay progressive artery damage in children
2. Statin use linked with decreased prostate cancer mortality rates, lower PSA levels
3. Statins linked to lower risk of infection
4. Statin users risk heart attacks by dropping treatment or taking low doses
5. Statins protect smokers from lung damage
6. Statins reduce risk of stroke in heart patients
7. Statin use associated with reduced risk of common type of cataract
8. Statins prove life-saving in patients with acute coronary syndromes
9. Statins may improve circulation in the retina
10. Statins, beta-blockers lessen heart attack risk, says Stanford-Kaiser study
11. Statins have neutral effect on risk of cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
Cached News: